The estimated Net Worth of Rajesh B Parekh is at least $2.9 Thousand dollars as of 13 May 2021. Rajesh Parekh owns over 2,466,666 units of Eloxx Pharmaceuticals Inc stock worth over $2,896 and over the last 15 years Rajesh sold ELOX stock worth over $0.
Rajesh has made over 2 trades of the Eloxx Pharmaceuticals Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Rajesh bought 2,466,666 units of ELOX stock worth $3,329,999 on 13 May 2021.
The largest trade Rajesh's ever made was buying 2,466,666 units of Eloxx Pharmaceuticals Inc stock on 13 May 2021 worth over $3,329,999. On average, Rajesh trades about 358,095 units every 556 days since 2009. As of 13 May 2021 Rajesh still owns at least 4,827,129 units of Eloxx Pharmaceuticals Inc stock.
You can see the complete history of Rajesh Parekh stock trades at the bottom of the page.
Rajesh's mailing address filed with the SEC is C/O ELOXX PHARMACEUTICALS, INC, 480 ARSENAL WAY, SUITE 130, WATERTOWN, MA, 02472.
Over the last 7 years, insiders at Eloxx Pharmaceuticals Inc have traded over $0 worth of Eloxx Pharmaceuticals Inc stock and bought 22,391,804 units worth $47,296,070 . The most active insiders traders include Ran Nussbaum, Tomer Kariv, and Steven D Rubin. On average, Eloxx Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $275. The most recent stock trade was executed by Alan Edmund Walts on 1 December 2021, trading 37,695 units of ELOX stock currently worth $23.
eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin
Eloxx Pharmaceuticals Inc executives and other stock owners filed with the SEC include: